Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Jimenez-Murcia S, Granero R, Larrea ST, Sauvaget A, Grall-Bronnec M, Alvarez-Moya EM, Aguera Z, Aymami N, Gomez-Pena M, del Pino-Gutierrez A, Moragas L, Menchon JM, Fagundo AB, Sauchelli S, La Verde M, Aguglia E, Signorelli MS, Formoso JAF, Fernandez-Aranda F. Pathological gambling and substance use disorders: effects of early incidence and personality. Drugs Health Society. 2015 Jan;14(1):78. doi: 10.7202/1035550ar
Raleigh VS, Irons R, Hawe E, Scobie S, Cook A, Reeves R, Petruckevitch A, Harrison J. Ethnic variations in the experiences of mental health service users in England: results of a national patient survey programme. Br J Psychiatry. 2007;191:304-12.
Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry. 1999 Dec;175:575-80. doi: 10.1192/bjp.175.6.576